After tumor formation, mice were grouped into two cohorts and received corresponding treatments as follows: mice harboring smaller tumors (mean volume 44.02mm3, n = 14) were injected intratumorally with PRM1 protein or PBS (control group 1), and those harboring larger tumors (mean volume 84.05mm3, n = 14) were treated with antibody against PRM1 or PBS (control group 2) (Fig. 6a). This evidence concerns the gene PRM1 and neoplasm.